MedTrace Logo

A Translational Study for Locoregional Recurrence of T4 Colon Cancer

NCT06958926 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-05-25

No results posted yet for this study

Summary

The outcome of T4 locally advanced colon cancer is poor when locoregional recurrence occurred. Previous studies had showed that the aggravation of T4 colon cancer is higher than N-positive colon cancer, contributing to staging paradox that outcomes of stage IIB/C are poorer than stage IIIA colon cancer and higher locoregional recurrence of stage IIB/C colon cancer. The phenomenon cannot be explained by radicality, lymph node harvested and adjuvant chemotherapy administration. To elucidate the cancerous aggravation of T4 colon cancer, the investigators should dive into the clinicopathology, metastatic mechanism and cancer biology.

The investigators hypothesize that peritoneal spreading can be one of the metastatic routes of T4 colon cancer; however, few studies have addressed the finding and deserved investigation. Previous research have found that serum epigenetic alterations and cell-free DNA can serve as a prognostic marker for stage II/III colon cancer.

Therefore, the aim of this study is (1) to explore the role of ascites cfDNA as a potential biomolecular marker for locoregional recurrence; (2) to identify the risk factors of locoregional recurrence for T4 colon cancer by correlating biomolecular markers between clinicopathology, epigenomic alterations in blood and ascites.

Conditions

  • T4 Colorectal Cancer
  • Colorectal Cancer Stage III
  • Colorectal Cancer Stage II

Interventions

PROCEDURE

Radical surgery for colon and rectum cancer

Radical surgery for colon and rectum cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.

PROCEDURE

Radical surgery for colorectal cancer

Radical surgery for colorectal cancer indicates that the surgery intends to eradicate all identifiable tumor in the human body.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yu-Tso Liao, MD, PhD · National Taiwan University Hospital Hsin-Chu Branch

  • Yu-Tso Liao · National Taiwan University Hospital Hsin-Chu Branch

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-14
Primary Completion
2025-12-31
Completion
2028-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06958926 on ClinicalTrials.gov